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The incidence and prevalence of non-tuberculous mycobacterial (NTM) infections have
been increasing worldwide and lately led to an emerging public health problem.
Among rapidly growing NTM, Mycobacterium abscessus is the most pathogenic
and drug resistant opportunistic germ, responsible for disease manifestations ranging
from “curable” skin infections to only “manageable” pulmonary disease. Challenges
in M. abscessus treatment stem from the bacteria’s high-level innate resistance and
comprise long, costly and non-standardized administration of antimicrobial agents, poor
treatment outcomes often related to adverse effects and drug toxicities, and high relapse
rates. Drug resistance in M. abscessus is conferred by an assortment of mechanisms.
Clinically acquired drug resistance is normally conferred by mutations in the target
genes. Intrinsic resistance is attributed to low permeability of M. abscessus cell envelope
as well as to (multi)drug export systems. However, expression of numerous enzymes
by M. abscessus, which can modify either the drug-target or the drug itself, is the
key factor for the pathogen’s phenomenal resistance to most classes of antibiotics
used for treatment of other moderate to severe infectious diseases, like macrolides,
aminoglycosides, rifamycins, β-lactams and tetracyclines. In 2009, when M. abscessus
genome sequence became available, several research groups worldwide started
studying M. abscessus antibiotic resistance mechanisms. At first, lack of tools for
M. abscessus genetic manipulation severely delayed research endeavors. Nevertheless,
the last 5 years, significant progress has been made towards the development of
conditional expression and homologous recombination systems for M. abscessus.
As a result of recent research efforts, an erythromycin ribosome methyltransferase,
two aminoglycoside acetyltransferases, an aminoglycoside phosphotransferase, a
rifamycin ADP-ribosyltransferase, a β-lactamase and a monooxygenase were identified
to frame the complex and multifaceted intrinsic resistome of M. abscessus, which
clearly contributes to complications in treatment of this highly resistant pathogen.
Better knowledge of the underlying mechanisms of drug resistance in M. abscessus
could improve selection of more effective chemotherapeutic regimen and promote
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development of novel antimicrobials which can overwhelm the existing resistance
mechanisms. This article reviews the currently elucidated molecular mechanisms of
antibiotic resistance in M. abscessus, with a focus on its drug-target-modifying and
drug-modifying enzymes.
Keywords: non-tuberculous mycobacteria, Mycobacterium abscessus, antibiotic, drug resistance, resistance
genes, antibiotic-target-modifying enzymes, antibiotic-modifying enzymes
INTRODUCTION
Non-tuberculous mycobacteria (NTM) encompass all species of
mycobacteria that do not cause tuberculosis (TB) or leprosy
(Lee et al., 2015). NTM are ubiquitous in the environment and
occasionally infect humans with various predisposing conditions
like cystic fibrosis, bronchiectasis or immunosuppression,
causing a variety of pathological conditions including pulmonary,
skin and soft tissue infections and disseminated diseases (Chan
and Iseman, 2013). The last few decades saw an alarming
increase in the incidence and prevalence of NTM-pulmonary
disease throughout the globe. Importantly, more than 90% of all
reported NTM-pulmonary disease cases involved infections with
the Mycobacterium avium complex (comprising of M. avium,
Mycobacterium chimaera and Mycobacterium intracellulare) or
Mycobacterium abscessus, accentuating the medical importance
of these emerging pathogens (Hoefsloot et al., 2013; Ryu et al.,
2016; Wu et al., 2018). For a long while, it was believed that
infections with genetically diverse NTM strains were exclusively
acquired upon exposure to the environment. However, a recent
whole genome analysis of more than 1000 M. abscessus clinical
isolates from different geographical locations, revealed the
presence of genetically clustered strains in patients. This suggests
a human-to-human transmission of M. abscessus, presumably
through indirect mechanisms like cough aerosols or surface
contamination (Bryant et al., 2016).
Mycobacterium abscessus is an opportunistic pathogen,
ubiquitous in the environment, that often causes infections in
humans with compromised natural defenses such as patients
with cystic fibrosis or other chronic lung diseases (Sanguinetti
et al., 2001; Brown-Elliott and Wallace, 2002; Howard, 2006;
Griffith et al., 2007). A current taxonomic classification suggests
separation of M. abscessus into three distinct subspecies:
M. abscessus subsp. abscessus, M. abscessus subsp. bolletii, and
M. abscessus subsp. massiliense (Tortoli et al., 2016). Although
a saprophyte in water and soil, following lung infection
M. abscessus can swiftly grow and survive intra-cellularly within
macrophages as well as in extra-cellular caseous lesions and
airway mucus (Wu et al., 2018). Several factors contribute to the
success of this rapidly growing mycobacterium. A plethora of
intrinsic resistance mechanisms renders almost all clinically used
antibiotics ineffective against M. abscessus (Nessar et al., 2012).
In addition, the presence of a highly dynamic open pan-genome
in M. abscessus might explain the ease with which the bacterium
evolves and adapts to a wide-spectrum of stressful environmental
conditions encountered in diverse habitats (Choo et al., 2014; Wu
et al., 2018). Importantly, the respiratory habitat of M. abscessus
brings it in close proximity to highly virulent pathogens (for
example, Pseudomonas aeruginosa in cystic fibrosis lung) which
can serve as donors of novel drug resistance or virulence genes
(Ripoll et al., 2009).
Treatment of an M. abscessus pulmonary infection is very
difficult owing to the bacterium’s high-level innate resistance
towards most antibiotics commonly used for Gram-negative
and Gram-positive bacterial infections including majority of
β-lactams, tetracyclines, aminoglycosides and macrolides. In
addition, anti-TB drugs including first-line drugs (such as
rifampicin and isoniazid) as well as some second-line agents
(such as capreomycin) are ineffective against this pathogen
(Table 1). Thus, the term “incurable nightmare” is often used
to describe M. abscessus (Brown-Elliott et al., 2012; Nessar et al.,
2012). So far, no reliable antibiotic regimen has been established
for M. abscessus pulmonary disease. Antibiotic administration is
largely empirical and relies on in vitro antibiotic susceptibility
testing and definitive subspecies identification (Griffith et al.,
2007; Ryu et al., 2016). Treatment of M. abscessus pulmonary
disease as recommended by the British Thoracic Society
involves administration of a multi-drug regimen encompassing
intravenous antibiotics - amikacin, tigecycline, and imipenem
along with an oral macrolide (clarithromycin or azithromycin)
for clinical isolates susceptible to macrolides, during the initial
treatment phase. For the continuation phase of treatment,
nebulised amikacin and an oral macrolide combined with one
to three of the following oral antibiotics: linezolid, clofazimine,
minocycline, co-trimoxazole, and moxifloxacin are generally
recommended (Haworth et al., 2017). Standard of care calls
for continuation of antibiotic therapy for a minimum of
12 months after culture conversion. However, microbiological
eradication of M. abscessus bacilli from lung tissues, using
recommended antibiotic regimens, is rare and recurrence is often
after completion of a treatment course and successful symptom
management (Jarand et al., 2011; Stout et al., 2016).
As a result of extensive, repeated or inappropriate use
of macrolides and aminoglycosides, which inhibit protein
biosynthesis by binding to the large and small ribosomal subunits,
respectively, M. abscessus strains with clinically acquired pan-
macrolide and pan-aminoglycoside resistance have emerged, due
to mutation(s) in the corresponding 23S (rrl) and 16S (rrs) rRNA
genes (Wallace et al., 1996; Prammananan et al., 1998; Maurer
et al., 2012; Nessar et al., 2012). Acquired resistance to macrolides
and aminoglycosides severely limits the remaining treatment
options and highlights the urgent need for new antimicrobial
agents.
Mechanisms underpinning intrinsic drug resistance of
M. abscessus are multi-fold and fall into two main groups:
first, the presence of a highly impermeable cell envelope
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TABLE 1 | Drug susceptibility of Mycobacterium abscessus wild-type and isogenic mutants in comparison to screening concentrations for M. tuberculosis with
decreased susceptibility.
Antimicrobial agent M. tuberculosis∗ (mg/L) M. abscessus MIC (mg/L) M. abscessus mutant MIC (mg/L) Reference
Isoniazid 0.1 >512 katG+ (M. tb): 32 Pers. Communication
Rifampicin 1.0 128 1arr: 0.25 Rominski et al., 2017a
Ethambutol 5.0 64 (polymorphism in target gene) N.A. Alcaide et al., 1997
Capreomycin 2.5 >256 1eis2: 4 Rominski et al., 2017c
Clarithromycin N.D. 64 1erm: 0.5 Choi et al., 2012
Kanamycin B N.D. 8 1aac(2′): 0.125 Rominski et al., 2017c
Amikacin 1.0 4 1eis2: 0.25 Rominski et al., 2017c
Streptomycin 1.0 32 1str(3′ ′): 2 Dal Molin et al., 2017
Tetracycline N.D. 60 1tetX: 4 Rudra et al., 2018
Amoxicillin N.D. >256 1bla: 8 Dubée et al., 2015
Ampicillin N.D. >256 1bla: 4 Dubée et al., 2015
Epidemiologic cutoff values (ECOFF; MGIT960) as defined by Cambau et al. (2015); MIC, minimal inhibitory concentration; N.A., Not available; N.D., Not determined.
and/or multi-drug eﬄux pumps might reduce the effective
concentration of antibiotics within the bacterial cells; second,
the genome of M. abscessus encodes several putative enzymes
which can inactivate antibiotics by modification and/or
degradation or lower the affinity of the drug for its target by
modifying the target (Ripoll et al., 2009; Nessar et al., 2012). For
long, molecular investigations aimed at elucidating antibiotic
resistance mechanisms of M. abscessus were limited, however,
significant progress has been made in recent years owing to
the development of efficient tools for genetic manipulation
of this bacterium (Figure 1). In this article, we provide an
up-to-date overview of the main molecular mechanisms of
antibiotic resistance in M. abscessus with a focus on the drug-
target-modifying or drug-modifying enzymes and discuss the
potential impact on clinical treatment. We also discuss how this
knowledge could facilitate the discovery and development of new
improved antimicrobial agents or help rescue the function of
currently available antibiotics against M. abscessus and provide
an update on the latest research underway to combat multi-drug
resistant M. abscessus infections.
ANTIBIOTIC-TARGET-MODIFYING
ENZYMES IN M. abscessus
Macrolide Resistance: MAB_2297
[erm(41)] Encoded Erythromycin
Ribosome Methylase
Macrolides are among the most successful antibiotics in the
world and are highly prescribed for infections caused by non-
tuberculous mycobacteria. A multidrug regimen recommended
for M. abscessus infections almost always includes macrolides,
particularly clarithromycin or azithromycin. Macrolides target
the nascent polypeptide exit tunnel within the 50S ribosomal
subunit, which accommodates the newly synthesized polypeptide
chain as it emerges from the ribosome. Following macrolide
binding, the elongation of polypeptide chain continues up
to a few amino acids before the peptidyl-tRNA dissociates
from the ribosome thereby arresting protein synthesis (Wilson,
2014).
In bacteria, innate resistance towards macrolides is most
often the result of increased eﬄux, ribosomal methyltransferases
and GTP-dependent macrolide kinases (Pawlowski et al., 2018).
A well-studied example of macrolide resistance by target
modification in bacteria is the erythromycin ribosome methylase
(Erm) enzyme, which specifically methylates A2058 nucleotide
of 23S rRNA and lowers the macrolide affinity for ribosome
exit tunnel (Blair et al., 2015). An Erm methyltransferase is also
responsible for inducible macrolide resistance in M. abscessus
(Figure 1). Interestingly, the erm(41) gene, first described by
Nash et al. (2009), is only functional in two out of three subspecies
of the M. abscessus complex. The subspecies M. massiliense
harbors deletions in its erm(41) gene copy which render the
Erm(41) enzyme inactive and the bacterium susceptible to
macrolides. This may explain why patients with M. massiliense
infections have better treatment outcomes than patients with
M. abscessus or M. bolletii infections. To further complicate
matters, a T/C polymorphism at position 28 of the erm(41)
sequence determines the appearance of inducible macrolide
resistance in M. bolletii and M. abscessus subspecies. Only
those isolates that harbor a T28 erm(41) sequevar develop
inducible macrolide resistance. Phenotypic detection of inducible
macrolide resistance in the M. abscessus complex by drug
susceptibility testing requires extended incubation (14 days
rather than 3 days) in the presence of the drug (Nash et al., 2009;
Kim et al., 2010).
A functional role of erm(41) in inducible resistance to
macrolides has been confirmed by genetic studies. Deletion
of erm(41) in M. abscessus lowered the minimal inhibitory
concentration (MIC) of clarithromycin by 128-fold (Table 1),
while introduction of a functional M. abscessus erm(41) gene into
M.massiliense led to a 64-fold increase in the clarithromycin MIC
on day 14 (Choi et al., 2012). Inducible Erm(41)-dependent rRNA
methylation severely affects the efficacy of macrolides against
M. abscessus. The long duration of partially effective macrolide
therapy, eventually favors the emergence of isolates with high-
level constitutive macrolide resistance. Mutations that alter the
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FIGURE 1 | Enzyme-mediated antibiotic resistance in Mycobacterium abscessus. M. abscessus is intrinsically resistant to a large and diverse array of antimicrobial
agents. The occurrence of several enzymes that can modify and/or degrade antibiotics or alter their targets in M. abscessus enables it to resist the action of multiple
classes of antibiotics. This figure provides an overview of the well-studied as well as some unexplored enzyme-mediated resistance mechanisms in M. abscessus.
Methylation of 23S rRNA by Erm(41), an erythromycin ribosome methylase, lowers the binding affinity of macrolides for the ribosome exit tunnel and confers
macrolide resistance. The expression of erm(41) gene in M. abscessus is induced upon exposure to macrolides, therefore this type of resistance by target
modification is known as inducible macrolide resistance. The addition of different chemical groups including acyl and phosphate groups to vulnerable sites on the
aminoglycoside molecule by M. abscessus enzymes can prevent the binding of aminoglycoside to its ribosomal target due to steric hindrance and result in
resistance. A diverse group of enzymes that differ in the aminoglycosides that they can modify as well as in the region of the antibiotic that is modified, are found in
M. abscessus. These include two putative acetyltransferases - AAC(2′) and Eis2 and one putative phosphotransferase - APH(3′ ′). The substrate aminoglycosides for
each enzyme are shown. In addition to aminoglycosides, Eis2 can also modify other ribosome-targeting antibiotics like capreomycin. Resistance to rifampicin and
other rifamycin antibiotics in M. abscessus involves covalent modification and drug inactivation by an ADP-ribosyltransferase, Arr_Mab. Apart from ADP-ribosylation,
two additional group transfer mechanisms of rifampicin inactivation including glycosylation, phosphorylation as well as decomposition of rifampicin by
monooxygenation, are widespread in environmental bacteria but have not been explored in mycobacteria. Being a saprophyte in soil, exposure to antibiotic
producing actinomycetes that utilize a variety of rifamycin inactivating mechanisms in its natural habitat might have favored the selection of an unknown reservoir of
rifamycin resistance genes in M. abscessus, for example, those encoding a rifamycin glycosyltransferase (Rgt_Mab) and/or a rifamycin monooxygenase (Rox_Mab)
(dashed lines). M. abscessus also produces a tetracycline-degrading flavin monooxygenase, MabTetX that activates molecular oxygen to hydroxylate and destabilize
the antibiotic, which subsequently undergoes non-enzymatic decomposition, thereby conferring resistance. Resistance to β-lactams in M. abscessus is afforded by
the production of a hydrolytic β-lactamase enzyme, Bla_Mab with the ability to degrade a broad range of β-lactams including extended-spectrum cephalosporins
and carbapenems. RNAP, RNA polymerase; PBPs, penicillin-binding proteins; AAC(2′), 2′-N-acetyltransferase; Eis2, enhanced intracellular survival protein 2;
APH(3′ ′), aminoglycoside 3′ ′-O-phosphotransferase.
23S rRNA nucleotides 2058 and 2059 within the peptidyl-
transferase center (PTC), are a frequent cause of constitutive
macrolide resistance in M. abscessus (Wallace et al., 1996; Bastian
et al., 2011; Brown-Elliott et al., 2015).
ANTIBIOTIC-MODIFYING ENZYMES IN
M. abscessus
Aminoglycoside Resistance: MAB_4395
[aac(2′)] & MAB_4532c (eis2) Encoded
Acetyltransferases; MAB_2385 Encoded
3′′-O-Phosphotransferase
Aminoglycosides are among the broadest classes of antibiotics
that interfere with specific steps in bacterial protein synthesis
(Kohanski et al., 2010). All aminoglycosides primarily target
the 16S rRNA component of 30S ribosomal subunit, however,
their exact binding site and mode of action may differ
slightly depending on their chemical structure. For example, 2-
deoxystreptamine (2-DOS) aminoglycosides (such as kanamycin,
amikacin, apramycin, arbekacin), which are chemically distinct
from the non-DOS aminoglycosides (for example, streptomycin),
specifically bind to the A-site region of small ribosomal subunit at
the decoding center, encompassing conserved nucleotides A1492
and A1493 of 16S rRNA. 2-DOS aminoglycosides function by
inhibiting the translocation of tRNA-mRNA complex through
the ribosome. Additionally, several members of this class also
induce protein mistranslation by promoting and stabilizing the
interaction of non-cognate aminoacylated tRNAs with mRNA.
In contrast, the non-DOS aminoglycoside streptomycin targets a
different region of 16S rRNA in proximity of the decoding center
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and mainly interferes with the delivery of aminoacylated tRNA to
the A-site (Wilson, 2014).
Bacterial resistance to aminoglycosides may occur due
to low cell permeability/eﬄux, mutations or modification
of 16S rRNA, mutations in ribosomal protein genes and
enzymatic drug modification. Drug and target modification
being the most extensively studied and clinically relevant
aminoglycoside resistance mechanisms in pathogenic bacteria.
Covalent modification of key amino or hydroxyl groups
within the aminoglycoside molecule by bacterial enzymes
markedly decreases the binding affinity for the ribosomal
target and confers aminoglycoside resistance. Aminoglycoside-
modifying enzymes in bacteria can be grouped into three main
classes namely, acetyltransferases, nucleotidyltransferases, and
phosphotransferases (D’Costa et al., 2011; Blair et al., 2015).
A worrying discovery that the genome of emerging pathogen
M. abscessus encodes several putative aminoglycoside-modifying
enzymes which include members of all three classes, came in
2009 when Ripoll et al first sequenced the complete genome
of M. abscessus (Ripoll et al., 2009). Some predictions were
later substantiated by drug susceptibility testing and biochemical
analysis (Maurer et al., 2015). More recently, direct genetic
evidence for a functional role of some of these putative
aminoglycoside-modifying enzymes in M. abscessus intrinsic
resistance to this antibiotic class, was obtained.
Similar to all other mycobacteria that have been studied
so far (Aínsa et al., 1997), M. abscessus also harbors a 2′-N-
acetyltransferase [AAC(2′)], encoded by MAB_4395 gene.
This enzyme is capable of acetylating several aminoglycosides
bearing a 2′ amino group including gentamicin C, dibekacin,
tobramycin and kanamycin B (Figure 1). This was evident
upon deletion of MAB_4395 in M. abscessus ATCC 19977
strain which led to a 4-64-fold reduction in the MICs of
these aminoglycosides (Table 1) (Rominski et al., 2017c).
Interestingly, another N-acetyltransferase capable of conferring
aminoglycoside resistance in M. abscessus is a homolog of
Anabaena variabilis enhanced intracellular survival (Eis) protein
(Figure 1). Eis proteins are widespread in mycobacteria as well
as other Gram-positive bacteria. Eis protein in Mycobacterium
tuberculosis has been shown to enhance intracellular survival
within macrophages by acetylating and activating dual-specificity
protein phosphatase 16/mitogen-activated protein kinase
phosphatase-7 (DUSP16/MPK-7), a JNK-specific phosphatase
that inhibits inflammation, autophagy and subsequent death
of infected macrophages (Shin et al., 2010; Kim et al., 2012).
Furthermore, upregulation of eis gene expression owing to
mutations in its promoter was associated with kanamycin
resistance in one-third of clinical isolates encompassing a large
collection of M. tuberculosis strains from diverse geographical
locations (Zaunbrecher et al., 2009). More recently, structural
and biochemical characterization of M. tuberculosis Eis revealed
its unprecedented ability to acetylate multiple amines of several
aminoglycosides (Chen et al., 2011).
Analysis of M. abscessus genome revealed two genes
namely, MAB_4124 (eis1) and MAB_4532c (eis2), which show
homology to eis from M. tuberculosis (Rv2416c) and A. variabilis
(Ava_4977), respectively. Drug susceptibility testing could
confirm a functional role for Eis2 but not Eis1, in intrinsic
aminoglycoside resistance. Of note, deletion of MAB_4532c
enhanced M. abscessus susceptibility towards a heterogenous
group of aminoglycosides including the cornerstone drug
amikacin as well as a non-aminoglycoside antibiotic capreomycin
(Table 1) (Rominski et al., 2017c). Furthermore, heterologous
expression of eis2 in Mycobacterium smegmatis decreased
amikacin susceptibility (Hurst-Hess et al., 2017). Capreomycin
is a cyclic peptide antibiotic that inhibits protein synthesis by
blocking peptidyl-tRNA translocation. The drug is particularly
active against M. tuberculosis and commonly used as a second-
line agent for the treatment of TB (Stanley et al., 2010; Wilson,
2014). Although remarkable, the discovery that M. abscessus
Eis2 exhibits a broad-spectrum acetyltransferase activity is not
a real surprise. In fact, recent structural and functional studies
on Eis enzymes from M. tuberculosis (Eis_Mtb), M. smegmatis
(Eis_Msm), and A. variabilis (Eis_Ava) revealed the presence
of an unusually large and complex active site unlike in other
aminoglycoside acetyltransferases. The unique structure equips
Eis with a regio-versatile multi-acetylating acetyltransferase
activity towards a broad range of substrates (Chen et al., 2012;
Pricer et al., 2012; Jennings et al., 2013). However, there seems
to be a notable difference between the acetylation activities of
M. abscessus Eis2 and M. tuberculosis Eis especially towards
capreomycin as the MIC of capreomycin in M. abscessus is about
100-fold higher than that in M. tuberculosis and this difference is
almost completely abolished by the deletion of eis2 gene (Table 1)
(Rominski et al., 2017c).
Aminoglycoside acetyltransferases Eis2 and AAC(2′) do
not appear to modify streptomycin, an aminoglycoside which
exhibits moderate in vitro activity against M. abscessus (MIC:
32 mg/L) (Rominski et al., 2017c). Instead, a MAB_2385
encoded putative aminoglycoside 3′′-O-phosphotransferase is
the main determinant for intrinsic streptomycin resistance
in M. abscessus (Figure 1). Twelve putative aminoglycoside
phosphotransferases are encoded in the genome of M. abscessus
(Ripoll et al., 2009). Among them, MAB_2385 was found to
be a close homolog of aph(3′′)-Ic, an aminoglycoside 3′′-O-
phosphotransferase gene which was previously shown to confer
streptomycin resistance in Mycobacterium fortuitum (Ramón-
García et al., 2006). Deletion of MAB_2385 enhanced the
susceptibility of M. abscessus towards streptomycin by 16-
fold (Table 1). Furthermore, MAB_2385 was able to confer
streptomycin resistance when heterologously expressed in
M. smegmatis (Dal Molin et al., 2017). To the best of our
knowledge other annotated aminoglycoside phosphotransferases
(such as MAB_0163c, MAB_0313c, MAB_0327, MAB_0951,
and MAB_1020) and aminoglycoside acetyltransferases (for
example, MAB_0247c, MAB_0404c, MAB_0745, MAB_4235c,
and MAB_4324c) have not been addressed experimentally,
however, interesting regulatory features of drug resistance genes
have been elucidated.
A WhiB7 like protein encoded by MAB_3508c was
recently uncovered as a multi-drug inducible transcriptional
regulator that modulates the expression of genes conferring
aminoglycoside and macrolide resistance in M. abscessus. WhiB7,
an autoregulatory transcriptional activator, is a determinant of
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innate antibiotic resistance in mycobacteria. In M. tuberculosis,
genes conferring antibiotic resistance including ermMT
(Rv1988), eis (Rv2416c) and tap (Rv1258c) are induced in
a whiB7-dependent manner, upon exposure to antibiotics.
Similarly, the erm(41) and eis2 genes in M. abscessus are included
in the whiB7 regulon (Hurst-Hess et al., 2017). A recent study
by Pryjma et al. (2017) demonstrated that exposure to sub-
inhibitory levels of clarithromycin, enhanced amikacin as well as
clarithromycin resistance in M. abscessus in a whiB7-dependent
manner. Of note, deletion of MAB_3508c rendered M. abscessus
more susceptible to amikacin (fourfold) and clarithromycin
(eightfold), while complementation with an intact gene copy
restored resistance to these antibiotics, suggesting a role of
whiB7 in M. abscessus amikacin and clarithromycin resistance.
Interestingly, pre-exposure to clarithromycin, which is a potent
inducer of M. abscessus whiB7, enhanced the resistance of
M. abscessus wild-type strain towards amikacin by fourfold but
had no effect on amikacin susceptibility of a 1whiB7 mutant. In
addition, pre-treatment with clarithromycin markedly increased
resistance to itself in the wild-type strain but did not alter
clarithromycin sensitivity of a 1whiB7 mutant. Furthermore, a
quantitative reverse transcription-PCR assay revealed a whiB7-
dependent upregulation of eis2 and erm(41) genes following
pre-exposure to clarithromycin. These observations support the
following conclusions: (i) in M. abscessus, whiB7 (MAB_3508c)
activates the expression of genes which confer amikacin and
clarithromycin resistance, i.e., eis2 and erm(41), (ii) strong
induction of whiB7 following exposure to clarithromycin confers
cross-resistance to amikacin in addition to activating inducible
macrolide resistance (Pryjma et al., 2017). Thus, in vitro findings
by Pryjma et al. (2017) suggest that front-line antibiotics,
amikacin and clarithromycin may exhibit antagonistic effects
when used in combination for the treatment of M. abscessus
infections. This may at least partially explain the limited clinical
efficacy of currently recommended multi-drug regimen for
M. abscessus which almost always includes these two antibiotics.
Tetracycline Resistance: MAB_1496c
Encoded Flavin Monooxygenase
Tetracyclines are a class of broad-spectrum natural product
antibiotics that interfere with bacterial protein synthesis. These
drugs bind with high affinity to the small ribosomal subunit
and specifically interfere with the delivery of aminoacylated
tRNA to the A-site (Kohanski et al., 2010; Wilson, 2014).
While tetracyclines are an important class of ribosome-targeting
antibiotics, their anthropogenic and prolific use in the clinic and
agriculture has led to emergence of resistance among benign
as well as pathogenic bacteria, thereby limiting their efficacy.
Despite growing resistance, tetracyclines continue to remain
one of the most successful and widely used chemotherapeutics
against bacterial infections (Allen et al., 2010). Furthermore, a
renaissance for tetracyclines is being fuelled by the development
of next-generation derivatives such as tigecycline, approved
for clinical use in 2005 and omadacycline and eravacycline,
undergoing late-phase clinical trials (Kinch and Patridge, 2014).
In fact, tigecycline is the only new antibiotic and the sole
member of its class, which has been introduced in the treatment
of recalcitrant M. abscessus lung disease with clinical evidence
(Wallace et al., 2014).
Previously, resistance towards tetracyclines was thought
to be exclusively mediated by two mechanisms namely,
drug eﬄux and ribosome protection. However, evidence for
enzymatic inactivation of tetracyclines by a family of flavin
adenine dinucleotide (FAD)-dependent monooxygenases
in both benign and pathogenic bacteria has been recently
documented. Few well characterized examples of such
tetracycline-modifying enzymes include TetX from the
obligate anaerobe Bacteroides fragilis and Tet(56) found in
human pathogen Legionella longbeachae, the causative agent
of Legionnaires’ disease and Pontiac fever (Yang et al., 2004;
Park et al., 2017). Whether such a mechanism of tetracycline
resistance existed in mycobacteria was not known until recently,
when Rudra and colleagues demonstrated through elegant
experiments, that high levels of intrinsic resistance towards
tetracycline and second generation derivative doxycycline in
M. abscessus was mediated by a flavin monooxygenase, MabTetX
(Figure 1). Deletion of MAB_1496c (encoding a putative
FAD binding monooxygenase) enhanced the susceptibility
of M. abscessus towards tetracycline and doxycycline by
15–20-fold (Table 1), while a complemented 1MAB_1496c
strain exhibited even higher levels of resistance towards both
antibiotics compared to the wild-type strain, supporting
the notion that MAB_1496c is a primary determinant for
M. abscessus intrinsic tetracycline resistance. Furthermore,
UV-Visible and mass spectrometry assays with purified
MAB_1496c protein provided evidence for hydroxylation and
subsequent degradation of tetracycline and doxycycline by
MabTetX (Rudra et al., 2018). Interestingly, MAB_1496c is not
a member of the whiB7 regulon, even though tetracycline is
a strong inducer of whiB7 in M. abscessus (Hurst-Hess et al.,
2017). In fact, MabTetX expression is regulated by a TetR
family repressor, MabTetRx (encoded by the upstream gene
MAB_1497c) which represses the MAB_1497c-MAB_1496c
operon by binding to a 35bp operator sequence tetO. This
repression is relieved in the presence of tetracycline and
doxycycline which can bind the repressor protein thereby
preventing its interaction with the tetO operator (Rudra et al.,
2018).
The glycylcycline antibiotic tigecycline, specifically designed
to evade resistance by ribosome protection and eﬄux, is
not invulnerable to modification by Bacteroides TetX, which
was recently also identified in numerous clinically relevant
pathogens (Volkers et al., 2011; Leski et al., 2013). Although
tigecycline was found to be a poor substrate of TetX, alarmingly
enzymatic activity of TetX was substantially improved upon
acquisition of single amino acid substitutions to confer
resistance at clinically relevant tigecycline concentrations
when overexpressed in Escherichia coli (Linkevicius et al.,
2016). Surprisingly, tigecycline resisted MabTetX-dependent
degradation and did not induce its expression, which might
contribute to its excellent in vitro activity and moderate clinical
efficacy against M. abscessus (Rudra et al., 2018). However,
selective pressure exerted by tigecycline will eventually favor
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the emergence of M. abscessus isolates carrying extended-
spectrum FAD-monooxygenases with the ability to modify
glycylcyclines.
Another interesting feature is the ability of
anhydrotetracycline (ATc), a degradation product of tetracycline
with poor antibiotic activity which was recently shown
to be a competitive inhibitor of TetX and Tet(56) flavin
monooxygenases, to rescue antibiotic activities of tetracycline
and doxycycline against M. abscessus expressing MabTetX (Park
et al., 2017; Rudra et al., 2018). However, ATc was also found to
induce MabTetX expression by binding the MabTetRx repressor,
a property at odds with its MabTetX inhibition activity. While
this finding together with the severe side effects associated with
ATc use, makes it an unattractive drug candidate, it nevertheless
represents a flexible starting point for developing MabTetX
inhibitors with improved activity, better tolerability and minimal
binding affinity towards MabTetRx. Co-administration with a
potent MabTetX monooxygenase inhibitor can potentially rescue
the clinical efficacies of tetracycline and doxycycline which are
currently inactive against the M. abscessus complex (Burgos et al.,
2011; Rudra et al., 2018).
β-Lactam Resistance: MAB_2875
Encoded β-Lactamase
β-lactams constitute an important class of antibiotics that
function by inhibiting cell wall synthesis in bacteria. The
β-lactam structure closely resembles the terminal D-alanyl-D-
alanine dipeptide of peptidoglycan, a substrate of penicillin
binding proteins (also known as D, D-transpeptidases) that
catalyze the final cross-linking step of peptidoglycan synthesis.
Penicilloylation of the D, D-transpeptidase active site following
treatment with β-lactams, disables the enzyme and prevents
the formation of peptidoglycan cross-links, thereby interfering
with cell wall biosynthesis (Kohanski et al., 2010). Despite
being the cornerstones of antimicrobial chemotherapy and
constituting one of the largest groups of antibiotics available
today, only two members of the β-lactam class namely, cefoxitin
(a cephalosporin) and imipenem (a carbapenem) form a part of
the antibiotic arsenal for M. abscessus. Furthermore, cefoxitin and
imipenem have been shown to exhibit only moderate in vitro
activity against M. abscessus with MICs of 32 and 4 mg/L,
respectively (Lavollay et al., 2014). Majority of the other β-lactam
antibiotics are not effective against this bacterium.
Several possible mechanisms may contribute to β-lactam
resistance in M. abscessus. Low mycomembrane permeability and
β-lactamase production may reduce the effective concentration
of β-lactams at the site of action. Alternatively, modification of
transpeptidase profile of the cell by replacement of penicillin
binding proteins (D, D-transpeptidases) with L, D-transpeptidases
for instance, may reduce the activity of penicillins and
cephalosporins that have lower affinity for L, D-transpeptidase
(Wivagg et al., 2014). However, most of the abovementioned
resistance mechanisms are relatively unexplored in this organism
except for one. Recently it was shown that the genome of
M. abscessus encodes a strong, constitutive class A β-lactamase
(Bla_Mab) which renders it highly resistant towards most
β-lactams (Figure 1). The M. abscessus β-lactamase Bla_Mab,
encoded by MAB_2875 is endowed with an exceptional broad-
spectrum activity and can effectively hydrolyse several members
of first- and second-generation cephalosporins, carbapenems,
and penams (Soroka et al., 2014). The currently recommended
β-lactams namely imipenem and cefoxitin are substrates of
Bla_Mab, however, they are hydrolysed at a very slow rate,
which may contribute to their clinical efficacy. The instability
of imipenem complicates drug susceptibility testing when
generation times of test bacteria require incubations for
several days as in the case of M. abscessus (Rominski et al.,
2017b).
One strategy to overcome the hurdle of chromosomally
encoded β-lactamase in M. abscessus is to co-administer
a β-lactamase inhibitor with the failing β-lactam. Soroka
and colleagues evaluated the in vitro efficacy of nitrocefin
and meropenem in combination with approved β-lactamase
inhibitors clavulanate, tazobactam, and sulbactam against
Bla_Mab. Surprisingly, Bla_Mab inhibition was not detected
for all the three inhibitor drugs (Soroka et al., 2014). This
remarkable ability of Bla_Mab to resist inhibition even surpasses
that of BlaC, a class A β-lactamase encoded by its relative
M. tuberculosis. Although BlaC is able to reverse inhibition
caused by tazobactam and sulbactam, and return to its native
functional form, clavulanate can slowly but irreversibly inhibit
this enzyme (Sagar et al., 2017). In fact, a recent demonstration
of in vitro synergy between meropenem and clavulanate in
13 extensively drug resistant (XDR) M. tuberculosis strains
raised a renewed interest in β-lactams for use in TB therapy
(Hugonnet et al., 2009). Fortunately, a surprising finding that
M. abscessus Bla_Mab is effectively disabled by the newly
approved β-lactamase inhibitor avibactam provides a new hope
for old antibiotics. A study by Dubée et al. (2015) showed that
co-administering a small amount of avibactam (4 mg/L) with
each of several representative antibiotics from three important
β-lactam sub-classes (carbapenems, penams, and cephalosporins)
lowered their MICs in M. abscessus CIP104536 strain to levels
comparable to those observed in a β-lactamase deficient mutant.
The authors also reported synergy between avibactam and
amoxicillin within macrophages as well as in a zebrafish model
of M. abscessus infection (Dubée et al., 2015). More recently,
an in vitro synergy screen of 110 β-lactam - β-lactamase
inhibitor combinations against an M. abscessus clinical isolate
identified six potential hits. Five selected β-lactamase inhibitors
encompassing both β-lactam-based (clavulanate, tazobactam,
and sulbactam) as well as non-β-lactam-based inhibitors
(avibactam and vaborbactam) were evaluated for synergistic
effects with a large panel of β-lactams. Importantly, all observed
synergy combinations exclusively involved non-β-lactam-based
inhibitors, either avibactam or vaborbactam. Combinations of
avibactam with each of the following drugs including ampicillin,
amoxicillin, tebipenem, and panipenem displayed synergistic
effects against M. abscessus. Furthermore, the carbapenems,
tebipenem, and panipenem also exhibited synergy with a novel
boronic acid β-lactamase inhibitor, vaborbactam (Aziz et al.,
2018). Thus, non-β-lactam-based β-lactamase inhibitors such as
avibactam and vaborbactam can potentially extend the spectrum
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of β-lactams employed for the treatment of largely incurable,
chronic M. abscessus pulmonary infections.
Rifamycin Resistance: MAB_0591
Encoded ADP-Ribosyltransferase
Rifampicin, a rifamycin antibiotic commonly employed as a first-
line agent in the treatment of M. tuberculosis infections, hardly
exhibits any activity towards the M. abscessus complex (MIC:
128 mg/L) (Table 1). Since rifamycins inhibit transcription by
binding with high affinity to rpoB encoded β-subunit of bacterial
RNA polymerase, resistance towards this group of antibiotics
is most commonly conferred by point mutations within the
target gene rpoB, especially in M. tuberculosis (Campbell et al.,
2001). However, additional rifamycin resistance mechanisms
that involve enzymatic drug inactivation are also prevalent in
other mycobacterial species. The presence of a rifamycin ADP-
ribosyltransferase in M. smegmatis was known for quite a while
(Quan et al., 1997), however, only recently genetic studies
involving gene knockout and heterologous expression unveiled
the existence of a MAB_0591 encoded ADP-ribosyltransferase
as the major determinant for high levels of innate rifamycin
resistance in M. abscessus (Figure 1). Deletion of MAB_0591
enhanced the susceptibility of M. abscessus towards three tested
rifamycins including rifaximin, rifapentine and rifampicin by
64–512-fold, respectively (Rominski et al., 2017a).
Surprisingly, a rifampicin derivative, rifabutin showed up
as an attractive hit (MIC: 2.5 mg/L), when a set of 2,700
FDA-approved drugs were screened against a clinical isolate of
M. abscessus. Rifabutin exhibited approximately 10-fold higher
potency in vitro relative to rifampicin and rifapentine, against
reference strains representative of all three subspecies of the
M. abscessus complex as well as a collection of clinical isolates
and its bactericidal activity was comparable to or better than that
of clarithromycin, one of the cornerstone drugs for M. abscessus
infections (Aziz et al., 2017). The higher efficacy of rifabutin
relative to rifampicin in M. abscessus as well as in M. tuberculosis
(with no known rifamycin inactivating enzymes) suggests its
increased accumulation within the bacterial cells. This may be
due to differences in membrane penetration or specificity of
eﬄux systems towards different rifamycins (Figure 1). Based on
the findings reported by Aziz et al. (2017), rifampicin analog
rifabutin, appears to be a potential candidate for repurposing
and its clinical efficacy in patients with M. abscessus pulmonary
disease should be further explored.
CLINICAL RELEVANCE
Although the inherent ability of M. abscessus to exhibit resistance
to a wide array of antibiotics has long been recognized,
our knowledge of the prodigious diversity of mechanisms
involved has improved immensely in recent years, owing to the
development of tools for genetic manipulation of M. abscessus.
A better understanding of the genetic basis of innate antibiotic
resistance is a prerequisite for the discovery and development of
synergistic drug combinations, where one agent serves to salvage
the antibacterial activity of a failing antibiotic by inhibiting an
intrinsic resistance mechanism. This is exemplified by the recent
discovery that avibactam is a potent inhibitor of M. abscessus
β-lactamase Bla_Mab. When used in combination, avibactam
lowered the MICs of several β-lactams in M. abscessus by
4–32-fold (Dubée et al., 2015; Kaushik et al., 2017). Despite the
success of β-lactamase inhibitors, the concept of designing drugs
which target intrinsic resistance mechanisms in bacteria, has
not gained substantial clinical exploitation beyond this antibiotic
class (Brown, 2015). Recently, a repertoire of drug-modifying
and target-modifying enzymes conferring innate resistance to
aminoglycosides, tetracyclines, rifamycins, and macrolides in
M. abscessus were delineated (Nash et al., 2009; Dal Molin et al.,
2017; Rominski et al., 2017a,c; Rudra et al., 2018). Likewise,
attempts to identify chemical entities which could potentially
rescue the function of one or more key members from each
aforementioned antibiotic group, should be pursued in the near
future.
Since the discovery that mutations within eis promoter are
associated with kanamycin resistance in M. tuberculosis, vigorous
attempts to identify Eis inhibitors that can potentially rescue
kanamycin activity in this pathogen have been pursued with
notable success. Recently, several structurally diverse competitive
Eis inhibitors with 1,2,4-triazino[5,6b]indole-3-thioether-based,
sulfonamide-based, pyrrolo[1,5-a]pyrazine-based and isothiazole
S,S-dioxide heterocyclic scaffolds were identified by high-
throughput screenings of large compound libraries. Importantly,
few promising inhibitors could completely restore kanamycin
susceptibility in a kanamycin resistant M. tuberculosis strain
in vitro at concentrations that were non-cytotoxic to mammalian
cells (Green et al., 2012; Garzan et al., 2016, 2017; Willby et al.,
2016; Ngo et al., 2018). Remarkably, inhibitors designed for
M. tuberculosis Eis, were also found to be active against Eis
homologs in M. smegmatis and A. variabilis (Chen et al., 2012;
Pricer et al., 2012). These findings give rise to an intriguing
possibility that Eis_Mtb inhibitors may be able to overcome
Eis2 mediated resistance towards aminoglycoside and/or non-
aminoglycoside antibiotics like capreomycin and restore their
effectiveness against M. abscessus. Hence efforts to explore the
activity of Eis_Mtb inhibitors against M. abscessus Eis2 enzyme
should be undertaken. Alternatively, extending drug discovery
efforts towards targeting WhiB7, could be a possible strategy
to tackle intrinsic macrolide and aminoglycoside resistance in
M. abscessus. WhiB7 is a conserved transcriptional regulator
in mycobacteria that co-ordinates intrinsic resistance to a wide
range of ribosome-targeting drugs (Burian et al., 2012). Recent
evidence suggests that genes which contribute to intrinsic
aminoglycoside and macrolide resistance in M. abscessus, i.e.,
eis2 and erm(41), are induced in a whiB7-dependent manner
upon exposure to ribosomal antibiotics (Hurst-Hess et al., 2017).
Thus, with the aim to kill two birds with one stone, compounds
that prevent the induction of eis2 and erm(41) resistance genes
in M. abscessus by modulating the synthesis and/or activity of
WhiB7, should be sought.
Since the discovery and development of compounds that
can circumvent existing resistance mechanisms in M. abscessus
is a daunting and time-consuming task, an immediate and
relatively simple solution to improve treatment efficacy may
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involve repurposing and repositioning of currently available
antibiotics. A number of candidate drugs suited for this
purpose have been reviewed in detail elsewhere (Wu et al.,
2018) and are therefore only briefly mentioned here. For
example, a systematic screening of a collection of FDA-approved
drugs revealed rifabutin, an analog of rifampicin, exhibiting
potent in vitro activity against M. abscessus (MIC: 2.5 mg/L)
(Aziz et al., 2017). Similarly, clofazimine, a leprosy drug
currently repurposed for treatment of TB, was also found
to be active against M. abscessus. In addition to promising
in vitro activity (MIC ≤ 1 mg/L), clofazimine displayed adequate
clinical efficacy and safety when evaluated in patients with
M. abscessus pulmonary infections (Yang et al., 2017). Likewise,
a novel oxazolidinone LCB01-0371, presently in Phase II clinical
development for TB, exhibited high potency against M. abscessus
compared to linezolid, an FDA-approved drug of the same class
(Kim et al., 2017). Moreover, some aminoglycosides such as
kanamycin A, apramycin, isepamicin, and arbekacin were also
found to exhibit potent in vitro activity against M. abscessus
(MICs ≤ 1 mg/L) (Rominski et al., 2017c). Besides these, other
compounds that have been extensively studied for their inhibitory
effects against M. abscessus encompass anti-TB drug bedaquiline,
some TB actives like indole-2-carboxamides and piperidinol-
based compound 1 (PIPD1), as well as second generation
thiacetazone derivatives like D6, D15, and D17 (Dupont et al.,
2016, 2017; Franz et al., 2017; Halloum et al., 2017; Kozikowski
et al., 2017).
In addition, several recent studies have reported in vitro
synergies between novel combinations of existing antibiotic
classes. For example, vancomycin, an inhibitor of cell wall
synthesis, exhibited synergy with clarithromycin, an inhibitor
of protein synthesis, in M. abscessus (Mukherjee et al., 2017).
Likewise, a combination of tigecycline (which inhibits protein
synthesis) with teicoplanin (which disrupts peptidoglycan
synthesis) displayed a strong synergistic effect against
M. abscessus (Aziz et al., 2018). Since the mycobacterial cell
envelope forms a major permeability barrier, drugs that perturb
cell wall integrity, are likely to synergize with drugs having
intracellular targets (Le Run et al., 2018). Such combinations
based on mechanistic drug action should be further explored for
synergistic effects against M. abscessus. For example, PIPD1 and
indole-2-carboxamides, which disrupt mycolic acid synthesis by
targeting MmpL3 transporter in mycobacteria (Dupont et al.,
2016; Franz et al., 2017), may be able to potentiate the effects of
other drugs modulating intracellular targets.
Taken together, a huge reservoir of intrinsic resistance genes
combined with an unusually high evolutionary potential of
its genome to acquire resistance renders almost all available
antibiotics ineffective against M. abscessus. Therefore, in the long
run, a better understanding of natural resistance mechanisms in
M. abscessus will help jump start drug discovery projects for (i)
compounds that can rescue current antibiotics by neutralizing
intrinsic resistance (termed antibiotic resistance breakers), (ii)
new drugs with one or more improved properties like ability to
resist enzymatic modification and/or degradation, high affinity
for modified or mutated targets, better solubility/uptake and
low propensity for eﬄux (Brown, 2015). In the short run,
available knowledge from studies seeking synergy between
antibiotics together with those investigating potential candidates
for repurposing, will aid in the development of dosing regimens
that display adequate clinical efficacy and resistance to which will
only emerge slowly.
OUTLOOK AND PERSPECTIVES
Molecular genetic tools that allow investigators to systematically
probe gene function in mycobacteria by generation of unmarked
gene deletions and functional complementation, have proven
extremely useful in dissecting the intrinsic resistome of
M. abscessus while genetic investigations in other NTM species
are still lagging behind. Using the available genetic ‘toolkit,’
7 orthologs of known resistance gene families have been
discovered so far in M. abscessus that provide resistance
or ‘immunity’ against antibiotics targeting major cellular
pathways including cell wall synthesis (β-lactams), RNA synthesis
(rifamycins) and protein synthesis (macrolides, aminoglycosides,
and tetracyclines). The impressive resistance diversity shown
by M. abscessus is expected given its natural habitat is shared
by many antibiotic producers, primarily the soil dwelling
actinomycetes which are also reservoirs of extensively diverse
resistance elements (Pawlowski et al., 2016; Crofts et al.,
2017; Koteva et al., 2018). Exposure to a variety of noxious
antimicrobial molecules in the soil might have favored selection
of specialized and diverse resistance mechanisms in M. abscessus
as well as in other NTM species.
Till now, the approach that researchers used to systematically
probe the intrinsic resistome of M. abscessus involved analysis
of few selected genes identified based on homology to known
resistance determinants from other bacteria. As a result, this
approach mainly revealed genes within M. abscessus that
were involved in previously known resistance mechanisms
and disguised the presence of potential determinants of
entirely new resistance mechanisms that lack characterized
homologs in other bacteria. To capture the remarkable resistance
diversity of M. abscessus as well as other environmental
NTM with unprecedented depth, future studies in this field
should incorporate next-generation approaches that provide
a comprehensive genome-wide definition of loci required for
antibiotic resistance, using cutting-edge technologies. One such
technique which can efficiently mine resistance determinants
with novel sequences as well as assign resistance functions to
known genes that were not previously shown to be involved
in drug resistance, is the most recent incarnation of insertional
mutagenesis, called transposon insertion sequencing (TIS) (Chao
et al., 2016).
The utility of TIS in elucidating novel antibiotic resistance
functions is highlighted by its recent application to the
discovery of a repertoire of previously unknown intrinsic factors
impacting resistance to antibiotics of different classes including
oxazolidinones, fluoroquinolones, and aminoglycosides in
pathogens of high clinical concern such as Staphylococcus
aureus, P. aeruginosa and E. coli (Gallagher et al., 2011; Shan
et al., 2015; Rajagopal et al., 2016). Screening large collections
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of transposon insertion mutants for antibiotic susceptibility
using TIS approach, has identified promising novel targets for
drugs that can restore or enhance susceptibility to existing
antibiotics. For example, analysis of insertion mutants spanning
all non-essential S. aureus genes for fitness defects resulting
from exposure to antibiotics, identified pathways/genes including
graRS and vraFG (graRS/vraFG), fmtA, mprF, SAOUHSC_01025,
and SAOUHSC_01050 which if inhibited, can greatly improve
the efficacy of existing antibiotics including daptomycin,
vancomycin, gentamicin, ciprofloxacin, oxacillin, and linezolid
and extend their utility for treating S. aureus infections
(Rajagopal et al., 2016).
In the coming years, high-throughput next-generation
strategies like TIS will undoubtedly rise to prominence in
the NTM drug resistance field and radically advance our
understanding of resistance mechanisms in M. abscessus
and other emerging NTM pathogens. Such breakthrough
technologies will greatly impact the kinds of questions which
can be addressed in this field, for example, which resistance
elements unique to M. abscessus render it unusually more drug
resistant than other NTM species? or does M. abscessus already
carry genes which confer resistance to novel NTM drugs in
development?
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